Leniobio Closes Its Series-A Extension Round And Strengthens Its Board Of Directors
Mar 07, 2022•over 3 years ago
Round Type
series a
Description
LenioBio GmbH, a German life sciences biotech offering a disruptive protein manufacturing technology, ALiCE®, closed its Series-A Extension round with a total investment volume of €11.5 million. The investment round, which was closed in November 2021, is led by LenioBio's current investor Bridford Group, a PE investor focusing on founder-led businesses with long-term growth potential and concerned with societal or environmental welfare.
FundzWatch™ Score
84
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood